Scientific publication by AdaptVac researchers about a capsid virus-like particle-based vaccine targeting IL-1β for treatment of allergic contact dermatitis
Hørsholm, Denmark, May 25, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the scientific journal Vaccines published an article authored by AdaptVac researchers about a capsid virus-like particle-based vaccine targeting IL-1β for treatment of allergic contact dermatitis.Excerpt: “…the data suggest that a cVLP-based vaccine displaying full-length IL-1β represents a promising vaccine candidate for use as an alternative treatment modality against severe ACD.” The scientific article is titled “Preclinical Efficacy of a Capsid